<DOC>
	<DOCNO>NCT02043587</DOCNO>
	<brief_summary>The objective protocol improve survival adult acute lymphoblastic leukemia acute lymphoblastic lymphoma reduce systemic central nervous system ( CNS ) relapse acceptable toxicity use intensive chemotherapy liposomal cytarabine ( Depocyt® ) CNS prophylaxis .</brief_summary>
	<brief_title>Chemotherapy With Liposomal Cytarabine CNS Prophylaxis Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma</brief_title>
	<detailed_description>This treatment regimen build `` Linker '' regimen/UCSF Protocol 8707 ALL regimen backbone goal improve efficacy acceptable toxicity substitute pegylated asparaginase native L-asparaginase , addition rituximab pre-B-cell ALL , addition dasatinib Philadelphia chromosome/BCR-ABL positive ALL , addition cyclophosphamide young adult . In addition , study regimen aim reduce CNS relapse use intrathecal liposomal cytarabine place intrathecal methotrexate CNS relapse prophylaxis The regimen use 3 module therapy non-cross-resistant chemotherapy agent . Rituximab add total 8 dos patient pre-B-cell ALL . Dasatinib add patient Ph+ ALL . Course 1A ( Induction ) : Daunorubicin , vincristine , PEG-asparaginase , prednisone patient addition cyclophosphamide patient 18-39 year age . Treatment intensified patient disease present day 14 bone marrow biopsy Induction Course 1A . In addition standard analysis , minimal residual disease assess day 14 remission bone marrow aspirate correlate outcome . Course 1B : High-dose methotrexate , oral 6-mercaptopurine , PEG-asparaginase . Course 1C : High-dose cytarabine etoposide . The 3 course repeat ( 2A ( Intensification ) , 2B , 2C ) follow final `` B '' cycle ( 3B ) high-dose methotrexate , 6-mercaptopurine , PEG-asparaginase . After completion Course 3B , patient proceed maintenance chemotherapy monthly methotrexate , vincristine , 6-mercaptopurine , prednisone cycle 24 month single dose PEG-asparaginase give month 1 Maintenance . CNS prophylaxis : Intrathecal liposomal cytarabine replaces intrathecal methotrexate CNS prophylaxis give every 2 week `` A '' Induction Intensification course every 3 month Maintenance total 8 dos . Given presence CNS penetrating chemotherapy `` B '' `` C '' cycle , intrathecal liposomal cytarabine give due risk excessive CNS toxicity . There randomization hydrocortisone placebo premedication prior PEG-asparaginase .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Ability understand willingness sign write informed consent . Diagnosis acute lymphoblastic leukemia lymphoblastic lymphoma define World Health Organization [ 94 ] Untreated disease EXCEPT corticosteroid , hydroxyurea , leukapheresis , and/or tyrosine kinase inhibitor 2 week prior initiation study therapy . Age 18 60 year ECOG performance status 0,1 , 2 ( see Appendix A ) Adequate organ function define : Total bilirubin &lt; 2 mg/dL ( unless due ALL ) AST ( SGOT ) /ALT ( SGPT ) &lt; 3 time institutional upper limit normal ( unless due ALL ) Serum creatinine &lt; 2 mg/dL ( unless elevate creatinine felt investigator acute reversible ) OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Left ventricular ejection fraction ≥50 % Women childbearing potential men partner child bear potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A woman childbearing potential female ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has undergone hysterectomy bilateral oophorectomy ; Has naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) Current anticipate use investigational agent study Known central nervous system mass lesion History allergic reaction attribute compound similar chemical biologic composition liposomal cytarabine agent use study inclusive know allergy polyethylene glycol . History unprovoked venous thrombosis/thromboembolism Recurrent chronic pancreatitis Uncontrolled diabetes mellitus Uncontrolled intercurrent illness would limit compliance study requirement include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant nursing . Any condition , opinion investigator , compromise compliance study requirement Known HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Lymphoblastic leukemia</keyword>
	<keyword>Lymphoblastic lymphoma</keyword>
</DOC>